| Literature DB >> 32566058 |
Igor Dumic1,2, Cristian Madrid2, Libardo Rueda Prada2, Charles W Nordstrom1,2, Pahnwat Tonya Taweesedt3, Poornima Ramanan4.
Abstract
Splenic complications of acute Babesia microti infection include splenomegaly, splenic infarct, and splenic rupture. These complications are relatively rarely reported, and the aim of this research was to synthetize data on this topic according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines using the PubMed database. In this review, we find that unlike other severe complications of babesiosis, splenic infarct and rupture occur in younger and immunocompetent patients, and they do not correlate with parasitemia level. Furthermore, admission hemoglobin of 10 mg/dl or less, platelet count of 50 × 10⁹/L or less, presence of hemodynamic instability, and splenic rupture were associated independently with an increased risk of requiring splenectomy. As babesiosis is an emerging tick-borne zoonosis, we hope that this review will help to raise awareness among clinicians regarding this rare but potentially life-threatening complication.Entities:
Year: 2020 PMID: 32566058 PMCID: PMC7275217 DOI: 10.1155/2020/6934149
Source DB: PubMed Journal: Can J Infect Dis Med Microbiol ISSN: 1712-9532 Impact factor: 2.471
Figure 1The flowchart delineates methodology and literature selection process according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses).
Demographic data, clinical features, management, and outcome of patients who developed splenic complications during acute Babesia microti infection.
| Case (ref) | Year (author) | Age | Sex | US state, country | Comorbid conditions | Symptoms duration PTP (days) | Dx missed initially | Remembers tick bite | SIRS/HD unstable on admission | Hgb (md/dl) | Platelet (×109/L) | Coinfection | Parasitemia level (%) | Splenomegaly | Type of splenic involvement PTA or AA | Transfusion (units) | ICS | Antibiotic treatment | Splenectomy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 [ | 2001 (Javed) | 85 | M | NJ, USA | HTN | Fever, chills, malaise (7–14) | Yes | No | No | 12 | 23 | Yes | 8 | No | I | Yes (2) | No | TCV + CLIN + QI | No, expired |
| 2 [ | 2008 (Kuwaya ma) | 61 | M | NJ, USA | None | Fever, chills, malaise, AP (180) intermittent | Yes | No (golfing) | No | 11 | 33 | No | 5 | Yes | R (AA) | Yes (4) | No | AZ + ATQ (7) | Yes |
| 3 [ | 2008 (Froberg) | 56 | M | MN, USA | HTN | Night sweats, malaise (NR) | Yes | NR | Yes | 9.3 | 37 | Yes (LD) | NR | Yes | R (AA) | NR | No | NR | Yes |
| 4 [ | 2008 (Florescu) | 58 | M | NJ, USA | None | Fever, AP, malaise, syncope (5) | Yes | No | No | 13.6 | 209 | APG | 0.5 | Yes | I | No | AZ + ATQ (NR) | No | |
| 5 [ | 2008 (Florescu) | 75 | F | NY, USA | HTN | Night sweats, malaise (NR) | Yes | No | Yes | 8.7 | 55 | No | NR | Yes (massive) | I | NR | No | AZ + ATQ QI + CLIN | No, expired |
| 6 [ | 2008 (Sidertis) | 50 | M | NJ, USA | None | Fever, AP, malaise, syncope (5) | Yes | No (golfing) | Yes | 9.3 | 458 | NR | 3 | Yes | R (PTA) | Yes (2) | No | AZ + ATQ (NR) | Yes |
| 7 [ | 2008 (Sidertis) | 71 | M | NJ, USA | NR | Syncope (NR) | No | NR | Yes | 9.2 | 72 | NR | NR | Yes | R (PTA) | Yes (2) | No | CLIN + QI (10) | Yes |
| 8 [ | 2011 (Tobler) | 54 | M | MA, USA | None | Nausea, chills, malaise, fever, AP (2) | No | No | No | 10.2 | 26 | No | 3 | Yes | R (PTA) | Yes (platelet) | No | AZ + ATQ (10) | No |
| 9 [ | 2011 (Abbas) | 23 | M | CT, USA | None | Fever, chills, weight loss, malaise LDN (0.5) | Yes | Yes | No | 6.8 | 78 | No | 30 | Yes | R (PTA) | Yes (4) | No | CLIN + QI (10) | No |
| 10 [ | 2011 (Reis) | 70 | M | NY, USA | NR | Fever, nausea, vomiting (3) | No | No | No | 8.5 | 90 | No | NR | Yes | R (PTA) | Yes (2) | No | AZ + ATQ (14) | No, SA embolization |
| 11 [ | 2011 (El Khouri) | 70 | M | NY, USA | None | Fever, chills, malaise (4) | No | NR | No | 10.1 | 77 | No | 8 | Yes | R (PTA) | Yes (3) | No | CLIN + QI AZ + ATQ (16) | No, SA embolization |
| 12 [ | 2011 (El Khouri) | 36 | M | NY, USA | None | Fever, headache, chills, cough (14) | No | NR | No | 8.5 | 133 | No | 3.5 | Yes | R (AA) | No | No | AZ + ATQ (21) | No |
| 13 [ | 2011 (Wormser) | 55 | M | RI, USA | Diverticulosis | Fever, rash, AP (10) | Yes | NR | Yes | 13.4 | 99 | NR | 0.1 | NR | R (PTA) | NR | No | AZ + ATQ (42) relapse after 10-day course | Yes |
| 14 [ | 2013 (Seible) | 83 | M | MA, USA | NR | Fever, nausea, AP (2) | No | NR | NR | NR | 66 | No | 14 | NR | R (PTA) | Yes exchange | No | CLIN + QI (30) | No |
| 15 [ | 2013 (Leinwan d) | 48 | M | CT, USA | None | Headache, AP, malaise (7) | No | No (camping) | No | 10.5 | 137 | No | 10 | Yes | R (PTA) | NR | No | AZ + ATQ (NS) | No observation |
| 16 [ | 2014 (Usatti) | 54 | M | CT, USA | None | Fever, headache, AP (2) | Yes | NR | Yes | 10.6 | 123 | No | NR | Yes | R (PTA) | Yes (2) | No | AZ + ATQ (10) | No |
| 17 [ | 2015 (Farber) | 59 | F | CT, USA | HLP depression | Fever, chills, syncope, fatigue, AP (14) | No | No (gardening) | Yes | 8.2 | 127 | No | 1 | Yes | R (PTA) | Yes (2) | No | CLIN + AZ + ATQ (14) | Yes |
| 18 [ | 2016 (Al Zoubi) | 72 | M | Ecuador | HTN | Fever, chills, weight loss, AP (NR) | Yes | NR | No | 7.8 | 55 | No | 0.5 | Yes | I | NR | No | ATQ + PRG (NR) | No |
| 19 [ | 2016 (Wong) | 56 | M | NY, USA | Diabetes | Fever, malaise, night sweats (6) | Yes | No (landscaping) | No | 10.7 | 163 | Yes (LD) | 1.5 | No | I | No | NO | AZ + ATQ (10) | No SA embolization |
| 20 [ | 2017 (Permpalu ng) | 59 | M | MA USA | MVP | Headache, fever, AP (14) | Yes | NR | NR | 10.4 | 156 | No | NR | Yes | I | No | No | AZ + ATQ (10) | No SA embolization |
| 21 [ | 2018 (Dumic) | 79 | F | WI, USA | HTN atrial fibrillation CAD | Chest pain, dizziness (1) | Yes | Yes | Yes | 6.5 | 6.5 | Yes (LD) | 1.3 | No | R (PTA) | Yes (4) | No | AZ + ATQ (10) Doxy (21) | Yes |
| 22 [ | 2018 (Blackwo od) | 51 | M | RI, USA | HTN atrial fibrillation | Fever, chills, malaise, AP (5) | No | Yes | Yes | 9.3 | 25 | NR | 0.25 | Yes | R (PTA) | Yes (4) | No | AZ + ATQ (14) | Yes |
| 23 [ | 2018 (Blackwo od) | 61 | M | RI, USA | HTN, HLP | Fever, chills, malaise, AP (3) | Yes | No (gardening) | Yes | 12.4 | 89 | NR | 0.44 | Yes | I | No | No | AZ + ATQ (NR) | No |
| 24 [ | 2018 (Li) | 48 | M | RI, USA | Asthma | Fever, chills, night sweats, AP (7) | NR | NR | No | 8.8 | 68 | NR | 0.22 | YES | R (NR) | NR | No | NR | No SA embolization |
| 25 [ | 2018 (Patel) | 48 | M | RI, USA | Asthma | Fever, chills, night sweats, AP (7) | NR | NR | No | 8.8 | 68 | NR | 0.22 | Yes | R (NR) | NR | No | NR | No SA embolization |
| 26 [ | 2018 (Patel) | 83 | M | RI, USA | CKD COPD | AP (1) | NR | NR | Yes | 11.3 | 94 | NR | 0.30 | NR | R (NR) | NR | No | NR | No |
| 27 [ | 2018 (Patel) | 40 | M | RI USA | Diabetes | Fever, malaise, night sweats (5) | NR | NR | No | 7.8 | 74 | NR | 0.07 | NR | R (NR) | NR | No | NR | No |
| 28 [ | 2018 (Patel) | 51 | M | RI, USA | HTN atrial fibrillation | Night sweats, headache, malaise, AP (3) | NR | NR | Yes | 8.7 | 25 | NR | 0.25 | 18.2 | R (NR) | NR | No | NR | Yes |
| 29 [ | 2018 (Patel) | 48 | M | RI, USA | None | Fatigue, AP (5) | NR | NR | Yes | 7.9 | 59 | NR | 0.26 | 16 | R (NR) | NR | No | NR | Yes |
| 30 [ | 2018 (Patel) | 36 | M | RI, USA | None | Fever, AP (4) | NR | NR | No | 10.6 | 80 | NR | 0.35 | NR | R (NR) | NR | No | NR | No |
| 31 [ | 2018 (Patel) | 68 | M | RI, USA | HTN | Malaise, AP (NR) | NR | NR | No | 6.6 | NR | NR | 5 | NR | R (NR) | NR | No | NR | No |
| 32 [ | 2018 (Kwon) | 50 | F | South Korea (imported from NJ, USA) | None | Headache, fever, AP, chills (NR) | Yes | NR (gardening) | No | 11.2 | 53 | NR | NR | NR | I | NR | No | ATQ/+AZ (NR) | No |
| 33 [ | 2019 (Alvi) | 60 | M | CT, USA | HTN, diabetes, HLP | Fever, chills, rigors, AP (7–10) | Yes | No | Yes | 10.2 | 36 | No | 11 | Yes | I | Yes | No | NS AZ + ATQ (14) | No observation |
| 34 [ | 2019 (Gupta) | 53 | M | NY, USA | None | Fever, chills, weakness (7) | No | No (hiking) | NR | 11.2 | 90 | NR | 1.5 | NR | I | No | No | AZ + ATQ (NS) | No observation |
A: azithromycin; AA: after admission; AP: abdominal pain; APG: Anaplasma phagocytophilum; ATQ: atovaquone; CKD: chronic kidney disease; CLIN: clindamycin; CT: Connecticut; Dx: diagnosis; E. ch: Ehrlichia chaffeensis; F: female; HA: headache; HD: hemodynamic; Hgb: hemoglobin, HLP: hyperlipidemia; HTN: hypertension; I: infarction; ICS immunocompromised state; LD: Lyme disease; LDN: lymphadenopathy; M: male; MA: Massachusetts; MN: Minnesota; MVP mitral valve prolapse; NJ: New Jersey; NR: not reported; NS: not specified; NY: New York; PRG: proguanil; PTA: prior to admission; PTP: prior to presentation; QI: quinine; R: rupture; Ref: reference; SA: splenic artery; TCV: ticarcillin-clavulanic acid “SIRS: systemic inflammatory response syndrome”.
Estimates of the linear probability model (LPM) for splenectomy.
| Dependent variable: splenectomy | LPM |
|---|---|
| Age ≥55 years | 0.2717 |
| Male | −0.0540 (0.1395) |
| Hypertension | −0.1861 (0.1419) |
| Hemoglobin <10 mg/dl | 0.2795 |
| Platelets < 50 × 109 | 0.3876 |
| Spleen rupture | 0.4359 |
| Hemodynamic instability | 0.4721 |
| Number of cases | 30 |
| R-squared | 0.6752 |
This table reports the estimates of a linear probability model (LMP) for the binary variable splenectomy. The R-squared value of 0.6752 indicates that 67.52% of the variance in the dependent variable (splenectomy) is explained by the regression model. It also has the simple interpretation that it equals the difference between the average predicted probability in the two groups. Because of the well-known heteroskedasticity in the LPM, heteroskedasticity-robust standard errors are reported in parentheses. p value <0.01, p value <0.05, and p value <0.1.